Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 940

1.

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.

Pediatr Infect Dis J. 2005 Jun;24(6):503-9.

PMID:
15933559
[PubMed - indexed for MEDLINE]
2.

Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.

Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.

AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1653-9.

PMID:
9870319
[PubMed - indexed for MEDLINE]
3.

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.

Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.

J Med Virol. 1999 Dec;59(4):507-11.

PMID:
10534734
[PubMed - indexed for MEDLINE]
4.
5.

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.

AIDS. 2003 Sep 5;17(13):1889-96.

PMID:
12960821
[PubMed - indexed for MEDLINE]
6.

Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.

Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.

AIDS. 1996 Jun;10(6):625-33.

PMID:
8780817
[PubMed - indexed for MEDLINE]
7.

HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, Lockman S, Fowler MG, Hanson C, Landesman S, Moye J, Rich KC, Zorrilla C, Japour AJ.

AIDS. 2000 Feb 18;14(3):263-71.

PMID:
10716502
[PubMed - indexed for MEDLINE]
8.

Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.

Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S.

J Virol. 1995 Jun;69(6):3510-6.

PMID:
7745698
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.

Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):136-44.

PMID:
9052722
[PubMed - indexed for MEDLINE]
10.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
[PubMed - indexed for MEDLINE]
Free Article
11.

Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.

Delta Coordinating Committee.

HIV Med. 2001 Jul;2(3):181-8.

PMID:
11737399
[PubMed - indexed for MEDLINE]
12.

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.

AIDS. 1998 Jun 18;12(9):1015-20.

PMID:
9662197
[PubMed - indexed for MEDLINE]
13.

Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.

Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M.

Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):274-82.

PMID:
10385016
[PubMed - indexed for MEDLINE]
14.

Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.

Masquelier B, Chaix ML, Burgard M, Lechenadec J, Doussin A, Simon F, Cottalorda J, Izopet J, Tamalet C, Douard D, Fleury H, Mayaux MJ, Blanche S, Rouzioux C; French Pediatric HIV Infection Study Group.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):99-104.

PMID:
11404530
[PubMed - indexed for MEDLINE]
15.

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.

McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.

J Pediatr. 1998 Oct;133(4):500-8.

PMID:
9787687
[PubMed - indexed for MEDLINE]
16.

Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.

Chong KT, Pagano PJ.

Antiviral Res. 1997 Mar;34(1):51-63.

PMID:
9107385
[PubMed - indexed for MEDLINE]
17.

A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.

Gatell JM, Leal M, Mallolas J, Vidal C, Pumarola T, Parra R, Padró S, Caruz A, Falgueras T, Rey C, Sánchez-Quijano A, Torres Y, Lissen E, Jiménez de Anta MT, Soriano E.

Antivir Ther. 1996 Apr;1(2):105-12.

PMID:
11321180
[PubMed - indexed for MEDLINE]
18.

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

Coakley EP, Gillis JM, Hammer SM.

AIDS. 2000 Jan 28;14(2):F9-15.

PMID:
10708277
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.

Cimoch PJ, Lavelle J, Pollard R, Griffy KG, Wong R, Tarnowski TL, Casserella S, Jung D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):227-34.

PMID:
9495222
[PubMed - indexed for MEDLINE]
20.

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. Erratum in: J Acquir Immune Defic Syndr. 2003 Jan;32(1):116..

PMID:
12473833
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk